Health-related Costs in a Sample of Premenopausal Non-diabetic Overweight or Obese Females in Antwerp Region: a Cost-of-illness Analysis

Overview

Journal Arch Public Health

Publisher Biomed Central

Date 2018 Aug 3

PMID 30069308

Citations 1

Authors

W Hens

D Vissers

L Annemans

J Gielen

L Van Gaal

J Taeymans

N Verhaeghe

Affiliations

Soon will be listed here.

Abstract

Background: People with overweight or obesity are at increased risk for disease later in life which cause important health costs.The aim of this study was to estimate the health status and the corresponding costs in a sample of females with overweight or obesity which were participating in a Randomized Controlled Trial (RCT) exploring the effect of lifestyle habits changes on ectopic adipose tissue.

Methods: Sixty-two non-diabetic premenopausal females without major comorbidities of overweight and obesity were recruited among patients visiting endocrinologists at the obesity clinic of the University Hospital of Antwerp and the University of Antwerp.A RCT-embedded cost-of-illness approach with societal perspective, based on self-reported questionnaires and cost diaries (3 months recall) was applied to estimate the prevalence of different comorbidities and the related direct and indirect costs in this sample of overweight or obese females. The European Quality-of-Life-5D questionnaire was used to define the health state and the corresponding utility index of the participants.

Results: The average direct health costs and health utilities observed in this sample were comparable with the general Flemish female population. This may partially be explained by the strict inclusion criteria of the RCT (i.e. overweight or obesity without diabetes type 2 or cardiovascular diseases). However, 15% of the participants had five or more comorbidities resulting in higher average costs and lower average health utility as compared to the general population, only 3 participants were diagnozed with the metabolic syndrome. In this subsample productivity was low due to high average absenteeism, yielding important total costs for the society.

Conclusion: Secondary prevention to avoid health deterioration in overweight or obese females without major comorbidies is needed to contain health care costs.

Trial Registration: ClinicalTrials.gov: NCT02831621, approval of the ethics committee of the University Hospital of Antwerp (number: 14/17/205 -ref: 7543075363).

Citing Articles

Unsupervised Exercise Training Was Not Found to Improve the Metabolic Health or Phenotype over a 6-Month Dietary Intervention: A Randomised Controlled Trial with an Embedded Economic Analysis.

Hens W, Vissers D, Verhaeghe N, Gielen J, Van Gaal L, Taeymans J Int J Environ Res Public Health. 2021; 18(15).

PMID: 34360293 PMC: 8345544. DOI: 10.3390/ijerph18158004.

References

Anis A, Zhang W, Bansback N, Guh D, Amarsi Z, Birmingham C . Obesity and overweight in Canada: an updated cost-of-illness study. Obes Rev. 2009; 11(1):31-40. DOI: 10.1111/j.1467-789X.2009.00579.x. View

Oliveira M, Santos L, Silva E . Direct healthcare cost of obesity in brazil: an application of the cost-of-illness method from the perspective of the public health system in 2011. PLoS One. 2015; 10(4):e0121160. PMC: 4382114. DOI: 10.1371/journal.pone.0121160. View

Alberti K, Zimmet P . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7):539-53. DOI: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. View

Boudreau D, Malone D, Raebel M, Fishman P, Nichols G, Feldstein A . Health care utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord. 2009; 7(4):305-14. DOI: 10.1089/met.2008.0070. View

Single E . Estimating the costs of substance abuse: implications to the estimation of the costs and benefits of gambling. J Gambl Stud. 2003; 19(2):215-33. DOI: 10.1023/a:1023633432745. View

Lette M, Bemelmans W, Breda J, Slobbe L, Dias J, Boshuizen H . Health care costs attributable to overweight calculated in a standardized way for three European countries. Eur J Health Econ. 2014; 17(1):61-9. PMC: 4705131. DOI: 10.1007/s10198-014-0655-8. View

Moore T, Caulkins J . How cost-of-illness studies can be made more useful for illicit drug policy analysis. Appl Health Econ Health Policy. 2006; 5(2):75-85. DOI: 10.2165/00148365-200605020-00002. View

Moreira G, Cipullo J, Ciorlia L, Cesarino C, Vilela-Martin J . Prevalence of metabolic syndrome: association with risk factors and cardiovascular complications in an urban population. PLoS One. 2014; 9(9):e105056. PMC: 4152120. DOI: 10.1371/journal.pone.0105056. View

van Hout B, Janssen M, Feng Y, Kohlmann T, Busschbach J, Golicki D . Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012; 15(5):708-15. DOI: 10.1016/j.jval.2012.02.008. View

10.

Sullivan M, Karlsson J, Sjostrom L, Backman L, Bengtsson C, Bouchard C . Swedish obese subjects (SOS)--an intervention study of obesity. Baseline evaluation of health and psychosocial functioning in the first 1743 subjects examined. Int J Obes Relat Metab Disord. 1993; 17(9):503-12. View

11.

Chang Y, Kim B, Yun K, Cho J, Zhang Y, Rampal S . Metabolically-healthy obesity and coronary artery calcification. J Am Coll Cardiol. 2014; 63(24):2679-86. DOI: 10.1016/j.jacc.2014.03.042. View

12.

Cawley J, Rizzo J, Haas K . Occupation-specific absenteeism costs associated with obesity and morbid obesity. J Occup Environ Med. 2008; 49(12):1317-24. DOI: 10.1097/JOM.0b013e31815b56a0. View

13.

Ul-Haq Z, Mackay D, Fenwick E, Pell J . Impact of metabolic comorbidity on the association between body mass index and health-related quality of life: a Scotland-wide cross-sectional study of 5,608 participants. BMC Public Health. 2012; 12:143. PMC: 3299597. DOI: 10.1186/1471-2458-12-143. View

14.

Goossens M, Rutten-van Molken M, Vlaeyen J, van der Linden S . The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol. 2000; 53(7):688-95. DOI: 10.1016/s0895-4356(99)00177-8. View

15.

Rosch M, Leidl R, von Tirpitz C, Reinshagen M, Adler G, Konig H . [Cost measurement based on a cost diary in patients with inflammatory bowel disease]. Z Gastroenterol. 2002; 40(4):217-28. DOI: 10.1055/s-2002-25153. View

16.

Allender S, Rayner M . The burden of overweight and obesity-related ill health in the UK. Obes Rev. 2007; 8(5):467-73. DOI: 10.1111/j.1467-789X.2007.00394.x. View

17.

Konnopka A, Bodemann M, Konig H . Health burden and costs of obesity and overweight in Germany. Eur J Health Econ. 2010; 12(4):345-52. DOI: 10.1007/s10198-010-0242-6. View

18.

Hamer M, Stamatakis E . Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab. 2012; 97(7):2482-8. PMC: 3387408. DOI: 10.1210/jc.2011-3475. View

19.

Verhaeghe N, Lievens D, Annemans L, Vander Laenen F, Putman K . The health-related social costs of alcohol in Belgium. BMC Public Health. 2017; 17(1):958. PMC: 5732489. DOI: 10.1186/s12889-017-4974-4. View

20.

Thorn J, Coast J, Cohen D, Hollingworth W, Knapp M, Noble S . Resource-use measurement based on patient recall: issues and challenges for economic evaluation. Appl Health Econ Health Policy. 2013; 11(3):155-61. DOI: 10.1007/s40258-013-0022-4. View